Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000895421-25-000232
Filing Date
2025-02-05
Accepted
2025-02-05 10:03:40
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7844
2 EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT EXHIBIT_NO.99.1.txt EX-99.1 CHARTER 1360
3 EXHIBIT NO. 99.2 ITEM 7 INFORMATION EXHIBIT_NO.99.2.txt EX-99.2 OPIN COUNSEL 669
  Complete submission text file 0000895421-25-000232.txt   11829
Mailing Address 1585 BROADWAY NEW YORK NY 10036
Business Address 1585 BROADWAY NEW YORK NY 10036 212-761-4000
MORGAN STANLEY (Filed by) CIK: 0000895421 (see all company filings)

EIN.: 363145972 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)

Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Subject) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89449 | Film No.: 25591242
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)